Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 289 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alopecia Areata Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia

NCT04409041
View directory record Official record
Conditions
Lichen Planopilaris, Frontal Fibrosing Alopecia
Interventions
Low-Dose Naltrexone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

the Safety, Tolerability and PK of KX-826 in Healthy Males With Alopecia Following Topical Multiple Dose Ascending

NCT04502901
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
KX0826, Placebo
Drug · Other
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Not applicable Interventional

Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors

NCT04764357
View directory record Official record
Conditions
Alopecia
Interventions
Paxman Scalp Cooling System, Alopecia Assessments, Patient Reported Outcomes Questionnaires
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
7 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)

NCT01451112
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
2
States / cities
Paramus, New Jersey • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of VDPHL01 in Males With AGA

NCT06724614
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01, Placebo
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fort Smith, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Not applicable Interventional

The Lily Device Trial

NCT06786078
View directory record Official record
Conditions
Chemotherapy Induced Alopecia
Interventions
Lily Device
Device
Lead sponsor
Luminate Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Mullica Hill, New Jersey • Vineland, New Jersey • Binghamton, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

NCT05398809
View directory record Official record
Conditions
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Interventions
Ruxolitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Not applicable Interventional Results available

A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

NCT05759338
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia
Interventions
Revian Red All LED cap
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Withdrawn Phase 2 Interventional

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

NCT03852992
View directory record Official record
Conditions
Male Pattern Hair Loss, Androgenetic Alopecia, Male Pattern Baldness
Interventions
Post-Laser Minoxidil 2%, At-Home Minoxidil 5%, Laser, Post-laser 5mg minoxidil, Post-laser 10mg minoxidil, Post-laser 20mg minoxidil
Drug · Device
Lead sponsor
University of Minnesota
Other
Eligibility
21 Years to 65 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Jun 7, 2026, 6:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata

NCT01385839
View directory record Official record
Conditions
Alopecia Areata, Alopecia, Balding
Interventions
Hair transplantation, Hypodermic needle irritation
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2016 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy of VDPHL01 in Males and Females With AGA

NCT06527365
View directory record Official record
Conditions
Androgenetic Alopecia, AGA, Male Pattern Baldness
Interventions
VDPHL01
Drug
Lead sponsor
Veradermics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
San Diego, California • New Albany, Indiana • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)

NCT01451177
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
3
States / cities
Los Angeles, California • Las Vegas, Nevada • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Utility of Platelet Rich Plasma in Hair Loss

NCT03376581
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Platelet rich plasma
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

NCT03899259
View directory record Official record
Conditions
Alopecia Areata
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
33
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fremont, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 7, 2026, 6:20 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

NCT06444451
View directory record Official record
Conditions
Alopecia Areata
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
17
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional

A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing

NCT02503137
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Topical SM04554 solution, Topical Vehicle solution
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Clinton Township, Michigan • Cleveland, Ohio • College Station, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jun 7, 2026, 6:20 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia

NCT01111981
View directory record Official record
Conditions
Alopecia
Interventions
Clobetasol Propionate 0.05% Emollient Foam
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mitchellville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Jun 7, 2026, 6:20 AM EDT
Not listed Phase 4 Interventional

Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia

NCT02999737
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Platelet Rich Plasma for 4 sessions, Platelet rich plasma for 2 sessions
Biological
Lead sponsor
Skin Care and Laser Physicians of Beverly Hills
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jun 7, 2026, 6:20 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

NCT05460611
View directory record Official record
Conditions
Scarring Alopecia, Androgenetic Alopecia
Interventions
Sciton HALO 1470nm Non-ablative laser
Device
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Elmsford, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, PP405 Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jun 7, 2026, 6:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Level Light Therapy (LLLT) for Hair Growth

NCT03938948
View directory record Official record
Conditions
Male Pattern Baldness, Female Pattern Baldness
Interventions
low-level laser/light therapy
Device
Lead sponsor
Awareable Technologies Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Ijamsville, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jun 7, 2026, 6:20 AM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

NCT02299297
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tofacitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jun 7, 2026, 6:20 AM EDT